Reverse engineering of the selective agonist TBPB unveils both orthosteric and allosteric modes of action at the M1 muscarinic acetylcholine receptor

Molecular Pharmacology

Volumn 84, Issue 3, 2013, Pages 425-437

  Keov, Peter ^a   Valant, Celine ^a   Devine, Shane M ^b   Lane, J Robert ^a   Scammells, Peter J ^b   Sexton, Patrick M ^a   Christopoulos, Arthur ^a  

^a MONASH UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1 (1' (2 METHYLBENZYL) 1,4' BIPIPERIDIN 4 YL) 1H BENZO[D]IMIDAZOL 2 (3H) 1; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC M1 RECEPTOR; MUSCARINIC M1 RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; DRUG BINDING SITE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; NONHUMAN; PRIORITY JOURNAL;

ALLOSTERIC REGULATION; ANIMALS; BENZIMIDAZOLES; BINDING SITES; BINDING, COMPETITIVE; CALCIUM; CHO CELLS; CRICETINAE; CRICETULUS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PIPERIDINES; RADIOLIGAND ASSAY; RECEPTOR, MUSCARINIC M1;

EID: 84883172335     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.087320     Document Type: Article

References (42)

1. Arunlakshana O and Schild HO (1959) Some quantitative uses of drug antagonists. Br Pharmacol Chemother 14: 48-58.
2. Avlani VA, Langmead CJ, Guida E, Wood MD, Tehan BG, Herdon HJ, Watson JM, Sexton PM, and Christopoulos A (2010) Orthosteric and allosteric modes of interaction of novel selective agonists of the M1 muscarinic acetylcholine receptor. Mol Pharmacol 78: 94-104.
3. Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, and Bymaster FP et al. (1997) Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 54: 465-473.
4. Bridges TM, Brady AE, Kennedy JP, Daniels RN, Miller NR, Kim K, Breininger ML, Gentry PR, Brogan JT, and Jones CK et al. (2008) Synthesis and SAR of analogues of the M1 allosteric agonist TBPB. Part I: Exploration of alternative benzyl and privileged structure moieties. Bioorg Med Chem Lett 18: 5439-5442.
5. Budzik B, Garzya V, Shi D, Walker G, Woolley-Roberts M, Pardoe J, Lucas A, Tehan B, Rivero RA, and Langmead CJ et al. (2010) Novel N-substituted benzimidazolones as potent, selective, CNS-penetrant, and orally active M1 mAChR agonists. ACS Med Chem Lett 1: 244-248.
6. Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJM, and Bymaster FP et al. (2008) Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci USA 105: 10978-10983.
7. Charlton SJ and Vauquelin G (2010) Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays. Br J Pharmacol 161: 1250-1265.
8. Cheng Y-C and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
9. Christopoulos A, Lanzafame A, and Mitchelson F (1998) Allosteric interactions at muscarinic cholinoceptors. Clin Exp Pharmacol Physiol 25: 185-194.
10. Christopoulos A, Loiacono R, and Mitchelson F (1993) Binding of the muscarine receptor antagonist heptane-1,7-bis(dimethyl-39-phthalimidopropyl) ammonium bromide at cholinoceptor sites. Eur J Pharmacol 246: 1-8.
11. Christopoulos A, Sorman JL, Mitchelson F, and El-Fakahany EE (1999) Characterization of the subtype selectivity of the allosteric modulator heptane-1,7-bis-(dimethyl- 39-phthalimidopropyl) ammonium bromide (C7/3-phth) at cloned muscarinic acetylcholine receptors. Biochem Pharmacol 57: 171-179.
12. Clark AL and Mitchelson F (1976) The inhibitory effect of gallamine on muscarinic receptors. Br J Pharmacol 58: 323-331.
13. Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8: 41-54.
14. Crespo P, Xu N, Simonds WF, and Gutkind JS (1994) Ras-dependent activation of MAP kinase pathway mediated by G-protein b g subunits. Nature 369: 418-420.
15. Digby GJ, Utley TJ, Lamsal A, Sevel C, Sheffler DJ, Lebois EP, Bridges TM, Wood MR, Niswender CM, and Lindsley CW et al. (2012) Chemical modification of the M (1) agonist VU0364572 reveals molecular switches in pharmacology and a bitopic binding mode. ACS Chem Neurosci 3: 1025-1036.
16. Ellis J, Huyler J, and Brann MR (1991) Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. Biochem Pharmacol 42: 1927-1932.
17. Evans BA, Broxton N,Merlin J, SatoM, Hutchinson DS, Christopoulos A, and Summers RJ (2011) Quantification of functional selectivity at the human a(1A)-adrenoceptor. Mol Pharmacol 79: 298-307.
18. Gregory KJ, Hall NE, Tobin AB, Sexton PM, and Christopoulos A (2010) Identification of orthosteric and allosteric site mutations in M2 muscarinic acetylcholine receptors that contribute to ligand-selective signaling bias. J Biol Chem 285: 7459-7474.
19. Jacobson MA, Kreatsoulas C, Pascarella DM, O'Brien JA, and Sur C (2010) The M1 muscarinic receptor allosteric agonists AC-42 and 1-[19-(2-methylbenzyl)- 1,49- bipiperidin-4-yl]-1,3-dihydro-2H-benzimidazol-2-one bind to a unique site distinct from the acetylcholine orthosteric site. Mol Pharmacol 78: 648-657.
20. Jakubík J, Bacáková L, el-Fakahany EE, and Tucek S (1995) Subtype selectivity of the positive allosteric action of alcuronium at cloned M1-M5 muscarinic acetylcholine receptors. J Pharmacol Exp Ther 274: 1077-1083.
21. Jones CK, Brady AE, Davis AA, Xiang Z, Bubser M, Tantawy MN, Kane AS, Bridges TM, Kennedy JP, and Bradley SR et al. (2008) Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J Neurosci 28: 10422-10433.
22. Kenakin T and Christopoulos A (2013) Signalling bias in new drug discovery: detection, quantification and therapeutic impact. Nat Rev Drug Discov 12: 205-216.
23. Kenakin T, Watson C, Muniz-Medina V, Christopoulos A, and Novick S (2012) A simple method for quantifying functional selectivity and agonist bias. ACS Chem Neurosci 3: 193-203.
24. Keov P, Sexton PM, and Christopoulos A (2011) Allosteric modulation of G proteincoupled receptors: a pharmacological perspective. Neuropharmacology 60: 24-35.
25. Langmead CJ, Austin NE, Branch CL, Brown JT, Buchanan KA, Davies CH, Forbes IT, Fry VAH, Hagan JJ, and Herdon HJ et al. (2008a) Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1. Br J Pharmacol 154: 1104-1115.
26. Langmead CJ, Watson J, and Reavill C (2008b) Muscarinic acetylcholine receptors as CNS drug targets. Pharmacol Ther 117: 232-243.
27. Lebois EP, Bridges TM, Lewis LM, Dawson ES, Kane AS, Xiang Z, Jadhav SB, Yin H, Kennedy JP, and Meiler J et al. (2010) Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M(1) receptor function in the central nervous system. ACS Chem Neurosci 1: 104-121.
28. Ma L, Seager MA, Wittmann M, Jacobson M, Bickel D, Burno M, Jones K, Graufelds VK, Xu G, and Pearson M et al. (2009) Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation. Proc Natl Acad Sci USA 106: 15950-15955.
29. Marlo JE, Niswender CM, Days EL, Bridges TM, Xiang Y, Rodriguez AL, Shirey JK, Brady AE, Nalywajko T, and Luo Q et al. (2009) Discovery and characterization of novel allosteric potentiators of M1 muscarinic receptors reveals multiple modes of activity. Mol Pharmacol 75: 577-588.
30. May LT, Avlani VA, Langmead CJ, Herdon HJ, Wood MD, Sexton PM, and Christopoulos A (2007) Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. Mol Pharmacol 72: 463-476.
31. Miller NR, Daniels RN, Bridges TM, Brady AE, Conn PJ, and Lindsley CW (2008) Synthesis and SAR of analogs of the M1 allosteric agonist TBPB. Part II: Amides, sulfonamides and ureas-the effect of capping the distal basic piperidine nitrogen. Bioorg Med Chem Lett 18: 5443-5447.
32. Narlawar R, Lane JR, Doddareddy M, Lin J, Brussee J, and Ijzerman AP (2010) Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. J Med Chem 53: 3028-3037.
33. Nawaratne V, Leach K, Suratman N, Loiacono RE, Felder CC, Armbruster BN, Roth BL, Sexton PM, and Christopoulos A (2008) New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol Pharmacol 74: 1119-1131.
34. Rosenblum K, Futter M, JonesM, Hulme EC, and Bliss TVP (2000) ERKI/II regulation by the muscarinic acetylcholine receptors in neurons. J Neurosci 20: 977-985.
35. Sheffler DJ, Sevel C, Le U, Lovell KM, Tarr JC, Carrington SJS, Cho HP, Digby GJ, Niswender CM, and Conn PJ et al. (2013) Further exploration of M1 allosteric agonists: subtle structural changes abolishM1 allosteric agonism and result in panmAChR orthosteric antagonism. Bioorg Med Chem Lett 23: 223-227.
36. Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, and Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165: 1033-1039.
37. Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, and Brann MR (2002) Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol Pharmacol 61: 1297-1302.
38. Stewart GD, Sexton PM, and Christopoulos A (2010) Prediction of functionally selective allosteric interactions at an M3 muscarinic acetylcholine receptor mutant using Saccharomyces cerevisiae. Mol Pharmacol 78: 205-214.
39. Stockton JM, Birdsall NJM, Burgen ASV, and Hulme EC (1983) Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 23: 551-557.
40. Valant C, Gregory KJ, Hall NE, Scammells PJ, Lew MJ, Sexton PM, and Christopoulos A (2008) A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J Biol Chem 283: 29312-29321.
41. Ward SDC, Curtis CAM, and Hulme EC (1999) Alanine-scanning mutagenesis of transmembrane domain 6 of the M(1) muscarinic acetylcholine receptor suggests that Tyr381 plays key roles in receptor function. Mol Pharmacol 56: 1031-1041.
42. Yamamoto S, Nishiyama S, Kawamata M, Ohba H, Wakuda T, Takei N, Tsukada H, and Domino EF (2011) Muscarinic receptor occupancy and cognitive impairment: a PET study with [11C](1)3-MPB and scopolamine in conscious monkeys. Neuropsychopharmacology 36: 1455-1465.